Canada - français - Health Canada

alcon canada inc - chlorhydrate de lévobunolol - liquide - 0.25% - chlorhydrate de lévobunolol 0.25% - beta-adrenergic agents

Canada - français - Health Canada

alcon canada inc - chlorhydrate de lévobunolol - liquide - 0.50% - chlorhydrate de lévobunolol 0.50% - beta-adrenergic agents

Canada - français - Health Canada

sandoz canada incorporated - chlorhydrate de lévobunolol - liquide - 0.25% - chlorhydrate de lévobunolol 0.25% - beta-adrenergic agents

Canada - français - Health Canada

sandoz canada incorporated - chlorhydrate de lévobunolol - liquide - 0.5% - chlorhydrate de lévobunolol 0.5% - beta-adrenergic agents

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

laboratoires alcon - chlorhydrate de lévobunolol - collyre - 0,5 g - composition pour 100 ml > chlorhydrate de lévobunolol : 0,5 g - atc s01ed03

Canada - français - Health Canada

teva canada limited - chlorhydrate de lévobunolol - solution - 0.25% - chlorhydrate de lévobunolol 0.25% - beta-adrenergic agents

Canada - français - Health Canada

teva canada limited - chlorhydrate de lévobunolol - solution - 0.5% - chlorhydrate de lévobunolol 0.5% - beta-adrenergic agents

Union européenne - français - EMA (European Medicines Agency)

koanaa healthcare gmbh - l'imatinib mésilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agents antinéoplasiques - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. les patients qui ont une faible ou très faible risque de récidive ne doit pas recevoir de traitement adjuvant. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. sauf dans les pays nouvellement diagnostiqué en phase chronique de la lmc, il n'y a pas d'essais contrôlés à démontrer un bénéfice clinique ou l'augmentation de la survie pour ces maladies.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ginsana sa - ginseng extractum ethanolicum siccum - pasticche - ginseng extractum ethanolicum siccum 15 - 27.5 mg corresp. ginsenosidea 2 mg, der: 3-7:1, aromatica, excipiens pro compresso. - tonico-stimolante - phytotherapeutika

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 et 5.